Please login to the form below

Not currently logged in
Email:
Password:

Kymriah

This page shows the latest Kymriah news and features for those working in and with pharma, biotech and healthcare.

Novartis: pipeline will generate 60 filings in three years

Novartis: pipeline will generate 60 filings in three years

Already active in this area with its lymphoma and leukaemia CAR-T therapy Kymriah (tisagenlecleucel), Novartis is highlighting new projects today including gene therapy AVXS101 for spinal muscular atrophy (SMA) type

Latest news

More from news
Approximately 8 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    manufacture and supply of Kymriah. $40m. Development. collaboration. Pfizer. Novartis to develop combination. ... Manufacture and supply of CAR‐ T cell therapy, Kymriah®, for B‐ cell acute lymphoblastic leukaemia.

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    therapies, such as CAR-Ts Kymriah and Yescarta.

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    Early signs are looking good: Novartis’Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June ... Kymriah and Yescarta might

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    drugs, Novartis’Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’gene therapy Luxturna all reaching the market last year. ... US prices for Novartis’Kymriah and Gilead’s Yescarta are $475, 000 and $373, 000, respectively, for the

  • No incentive for a cure No incentive for a cure

    These include Kymriah, the pioneering CAR-T cell therapy from Novartis, which demonstrated a remarkable 83% remission rate in children and young adults with B-cell precursor acute lymphoblastic leukaemia. ... assessment found a price of $600, 000-750,

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • Training the next generation of biotech leaders

    In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’ s Yescarta in October. ... Kymriah, which make it into routine practice as a first-line treatment.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics